Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133611 | 0.91 | HTT (0.44) | HSD17B10KDM4ESMN1; SMN2HTTTP53 | |
| SCHEMBL6133402 | 0.89 | KDM4E (0.41) | HSD17B10KDM4EHTTTP53CYP1A2 | |
| SCHEMBL6133474 | 0.87 | HTT (0.50) | HSD17B10KDM4ESMN1; SMN2HTTTP53 | |
| SCHEMBL6133443 | 0.87 | HSD17B10 (0.50) | HSD17B10KDM4ESMN1; SMN2HTTTP53 | |
| SCHEMBL6133496 | 0.86 | KDM4E (0.54) | HSD17B10KDM4ESMN1; SMN2HTTTP53 | |
| SCHEMBL6133994 | 0.85 | ALDH1A1 (0.46) | KDM4EHTTADORA1POLB | |
| SCHEMBL6133346 | 0.84 | ALDH1A1 (0.49) | HSD17B10KDM4ESMN1; SMN2HTTTP53 | |
| SCHEMBL6134015 | 0.84 | KDM4E (0.45) | HSD17B10KDM4ESMN1; SMN2HTTTP53 | |
| SCHEMBL6133697 | 0.84 | HSD17B10 (0.46) | HSD17B10KDM4ESMN1; SMN2HTTTP53 | |
| SCHEMBL6133820 | 0.82 | KDM4E (0.52) | HSD17B10KDM4ESMN1; SMN2HTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1441732-A2 | THIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003039451-A2 | THIAZOLE PYRIDAZINONES AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | MC2R, CYP2C9, OXTR | HSD17B10 391/4885KDM4E 3814/4885SMN1; SMN2 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.